GlassScriptPhysician profile
John A Fry
NPI 1760541056
$3,087.31
in general payments reported to CMS, 2019-2025
33 companies · $777 in 2025
The $777 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $85.17 · 2021: $312 · 2022: $838 · 2023: $504 · 2024: $379 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.70 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $458.31 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $435.79 | 2023-2025 | Avvigo Guidance System, Watchman Flx |
| Medtronic, INC. | $317.92 | 2023-2025 | Symplicity G3, Onyx Frontier |
| Janssen Pharmaceuticals, INC | $248.44 | 2020-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $201.72 | 2021-2025 | |
| Recor Medical INC | $143.12 | 2024 | Paradise Renal Denervation System |
| Galderma Laboratories, L.P. | $124.48 | 2019 | |
| Pfizer INC. | $117.56 | 2021-2023 | |
| Abiomed | $116.81 | 2025 | |
| Merck Sharp & Dohme LLC | $115.91 | 2021-2023 | Verquvo, Steglatro |
| Philips North America LLC | $107.13 | 2019-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| E.R. Squibb & Sons, L.L.C. | $99.21 | 2021-2023 | Eliquis |
| Abbott Laboratories | $70.93 | 2021-2022 | |
| Teleflex LLC | $43.86 | 2024 | Pronto, Guardian |
| Imperative Care, INC | $43.02 | 2024 | Symphony Catheter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.49 | 2021-2022 | |
| Irhythm Technologies, INC. | $39.67 | 2024 | Zio Xt Patch, Zio Monitor |
| Cvrx, INC. | $39.62 | 2021-2023 | Barostim Neo System |
| Medtronic Vascular, INC. | $34.37 | 2020 | |
| Angiodynamics, INC. | $33.62 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $33.00 | 2022-2023 | |
| Terumo Medical Corporation | $30.20 | 2022-2025 | Optitorque, Glidesheath Slender, Metacross Otw |
| Allergan, INC. | $26.87 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.33 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.01 | 2023 | |
| Edwards Lifesciences Corporation | $17.50 | 2021 | |
| Bard Peripheral Vascular, INC. | $16.57 | 2021 | |
| Novo Nordisk INC | $16.27 | 2025 | Ozempic |
| Cardiva Medical, INC. | $15.44 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Cardinal Health 200 LLC | $15.29 | 2019 | |
| Daiichi Sankyo INC. | $15.19 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.34 | 2021 | |
| G Medical Diagnostic Services, INC. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.